Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Antiviral

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Antiviral

28 Sep 2014 - 01 Oct 2014

El Jadida, Morocco

Synopsis

*Thank you to our media partners; the European Society for Virology and the Journal of General Virology.*

The four day conference will focus on Antiviral Research with a combination of plenary lectures, invited lectures and contributing talks which will be selected from the open abstract submissions (submissions can be uploaded upon registration). A broad range of topics will be covered focusing on the latest clinical practice, as well as the discovery and development of antiviral agents for the treatment and cure of various infectious agents. 

Key Sessions

  • HIV (Treatment)
  • HIV (Eradication)
  • HBV
  • HCV
  • Respiratory Viruses
  • Vector Borne Viruses
  • Norovirus & Emerging Viruses
  • Herpes Viruses
  • Global Pandemics

Our speakers will discuss the latest developments and cutting edge research and look to address the question “What is next for the industry?” The purpose of this conference is to provide a platform for discussion, collaboration and free exchange of ideas, allowing all participants to present their work either as a talk or in poster form. 

Educational Objectives

The conference will address the following learning objectives:

  1. Update participants on the overall progress in antiviral research
  2. Inform clinicians of their choices in patient treatments with existing licenced antiviral therapies
  3. Describe the pipeline of new compounds in development and their likely impact on patient treatments
  4. Enhance the understanding of participants of the development of resistance to antiviral drugs and the importance of treatment selection and adherence to the correct dosing regimens
  5. Evaluate the unmet needs for antiviral drugs to guide both academic and industry participants in their choice of research topics
  6. Help participants foresee the impact of the latest discoveries in virology on the search for new therapies.

Target Audience

This conference will look to bridge the gap between clinical practise, industry and academia and will actively encourage the participation MDs, clinicians, nurses, clinical lab directors, clinical service planners, academic researchers and pharmaceutical industry representatives.

Confirmed Plenary Speakers

Daria Hazuda
Merck 
Mario Stevenson
University of Miami Health System
Michael Manns
Hannover Medical School 
Guey Chuen (Oscar) Perng
National Cheng Kung University
Brent Korba
Georgetown University
Helga Rubsamen-Schaeff
AiCuris
Yves Benhamou
Hôpital Pitié-Salpêtrière

Confirmed Invited Speakers

Baek Kim
Emory University
Carol Brosgart
Viral Hepatitis Action Coalition, CDC Foundation
Leonid Margolis
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Massimo Levrero
Sapienza Universita' di Roma
Osvaldo (Lalo) Flores
Novira Therapeutics 
Tarik Asselah
University Paris Diderot

Sponsors

Sponsors

Programme

Sunday 28th September 2014

20:00

Group Dinner (Meeting Point: Market Place Buffet Restaurant)

Monday 29th September 2014

HIV (Eradication/Treatment) I
Session Chair: Raymond Schinazi

08:20 – 08:30

Opening Comments

08:30 – 09:00

Tariq Rana
UCSD School of Medicine

TARGETING VIF REGULATORY AXIS: DEVELOPING NEW AIDS THERAPIES

09:00 – 09:45

Mario Stevenson
University of Miami Miller School of Medicine

 

09:45 – 10:00

Carole Devaux
CRP-Sante

IDENTIFICATION OF A SMALL HIV-1 NEUTRALIZING ANTIBODY FRAGMENT MIMICKING THE CXCR4 AND CCR5 SURFACE IN A VIREMIC CONTROLLER

10:00 – 10:30

Refreshments

HIV (Eradication/Treatment) II
Session Chair: Raymond Schinazi

10:30 – 11:15

Daria Hazuda
Merck

HIV LATENCY DRUG DISCOVERY:  OPTIMIZING DRUGS TO INDUCE LATENT HIV EXPRESSION

11:15 – 11:45

Baek Kim
Emory University

Vpx CONTRIBUTES TO INSENSITIVITY OF SIV to NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

11:45 – 12:15

Panel Discussion

12:15 – 17:00

Group Lunch in Olives Buffet Restaurant & Free Time

14:00 – 17:00

Group Tour to El Jadida (Meeting Point: Hotel Lobby)

HBV & HCV
Session Chair: Raymond Schinazi

17:00 – 17:30

Massimo Levrero
Sapienza University of Rome

CAN WE ELIMINATE OR SILENCE THE CCCDNA AND CURE CHB?

17:30 – 18:00

Lalo Flores
Novira Therapeutics

CORE INHIBITORS: AN ATTRACTIVE NOVEL CLASS OF HBV DRUGS THAT  PROMISES TO INCREASE FUNCTIONAL CURES RATES

18:00 –18:30

Refreshments

18:30 – 19:15

Michael P. Manns
Medizinische Hochschule Hannover

HEPATITIS C: FROM VIRUS DISCOVERY TO CURE
(Presented by Tarik Asselah)

19:15 – 19:45

Tarik Asselah
Service d’Hépatologie

INTERFERON-FREE TREATMENT WITH DIRECT ACTING ANTIVIRALS FOR HEPATITIS C: PERSPECTIVES FOR HCV ERADICATION

19:45 – 20:15

Panel Discussion

20:15

Group Dinner (Market Place Buffet Restaurant)

Tuesday 30th September 2014

Herpesviruses
Session Chair: Kenneth Powell

08:30 – 09:15

Helga Rübsamen-Schaeff
AiCuris GmbH & Co. KG

NOVEL THERAPEUTIC APPROACHES AGAINST HERPESVIRUSES

09:15 – 09:45

Leonid Margolis
NIH

HERPESVIRUSES: HIV EVIL ASSOCIATES

09:45 – 10:15

Panel Discussion

10:15 – 10:45

Refreshments

Vector Borne, Norovirus & Emerging Viruses
Session Chair: Kenneth Powell

10:45 – 11:30

Brent Korba
Georgetown University Medical Center

NOROVIRUS CONTAINS DIVERSE AND UNIQUE ANTIVIRAL TARGETS

11:30 – 12:15

 

Oscar Perng
National Cheng Kung University

 

12:15 – 12:45

Panel Discussion

12:45 – 17:00

Group Lunch in Olives Buffet Restaurant & Free Time

Respiratory Viruses
Session Chair: Kenneth Powell

17:00 – 17:45

Kenneth Powell
Q-Chip Ltd

DEVELOPMENT OF NOVEL COMPOUNDS TO TREAT RSV INFECTION

17:45 – 18:00

James Mahony
St. Joseph's Healthcare Hamilton

CREATION OF NOVEL ANTIVIRALS FOR RESPIRATORY VIRUSES USING SINGLE DOMAIN ANTIBODIES (mFc) AND PEPTIDE INHIBITORS AS THERAPEUTIC FUSION PROTEINS

18:00 – 18:30

Panel Discussion

18:30 – 19:00

Refreshments

Special Plenary

19:00 – 19:45

Raymond F. Schinazi
Emory University School of Medicine

Curing HCV: The best is yet to come

20:00 – 23:00

Gala Night & Group Photo in Morjana Restaurant

 

Speakers

Plenary Speakers

Invited Speakers

  • Dr. Baek Kim
    Director of Drug Discovery, Emory University
  • Prof. Massimo Levrero
    Professor of Medicine, Sapienza University of Rome
  • President & CSO Lalo Flores
    President & CSO, Novira Therapeutics
  • Dr. Leonid Margolis
    Section Chief, NIH
  • Prof. Dr. Tariq Rana
    Professor and V/C, UCSD School of Medicine

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr